جست‌وجوی استاد و پژوهشگر

Miriam Breunigمشاهده پروفایل

دانشیار

• Pharmaceutical Technology
• Nanomedicine
• Drug Delivery Systems
• +۷ مورد دیگر

apl. Prof. Dr. Miriam Breunig is Associate Professor (apl. Prof.) of Pharmaceutical Technology at the University of Regensburg, Germany, and heads a research group developing nanoparticle-based drug- and vaccine-delivery systems. Since 2023 she serves as Co-Editor-in-Chief of the European Journal of Pharmaceutics and Biopharmaceutics and in 2024 was appointed Galenus Foundation Guest Professor at MIT. Education & Career: 1996-2001: Undergraduate pharmacy studies, Ruprecht-Karls-University Heidelberg 2002-2005: Graduate researcher, Univ. Regensburg (Prof. Göpferich) 2008 & 2009: Post-doctoral fellow, MIT (Prof. Robert Langer) 2013: Habilitation in Pharmaceutical Technology, Univ. Regensburg since 2012: Akademische Rätin (Associate Professor), Dept. Pharmaceutical Technology, Univ. Regensburg Research Focus: The Breunig group engineers innovative delivery platforms for small molecules, proteins and nucleic acids. Core projects include silica- and mesoporous-silica nanoparticle vaccines against HIV-1 and SARS-CoV-2 , injectable hydrogels that provide sustained nanoparticulate antigen release for single-dose immunisation, and nanoparticle-based glaucoma therapy targeting the trabecular meshwork/Schlemm's canal with siRNA or ROCK inhibitors. Publication Trends: Recent articles (2020-2024) concentrate on multivalent antigen display on silica nanoparticles to enhance B-cell activation and durable antibody responses, long-acting hydrogel depots for HIV vaccines, ocular nanoparticle targeting for glaucoma, and mechanistic studies on nanoparticle functionalisation, ECM penetration and controlled release. Editorial & Honours: Co-Editor-in-Chief, Eur J Pharm Biopharm (since 2023) Co-Editor, same journal (2013-2023) Galenus Foundation Guest Professor, MIT (2024) Collaborations & Funding: She coordinates projects within the HIVacToGC consortium, collaborates with Prof. Mika Lindén (mesoporous silica), Prof. Rudolf Fuchshofer (ocular pharmacology) and partners at MIT, and has secured funding for vaccine and glaucoma nanomedicine initiatives.

Sumati Bhatiaمشاهده پروفایل

مدرس ارشد

• Glycomaterials
• Antimicrobials
• Polymers
• +۷ مورد دیگر

Dr. Sumati Bhatia is a Senior Lecturer in Chemistry at Swansea University's Faculty of Science and Engineering, specializing in biomacromolecular chemistry and glycomaterials research. Her work focuses on engineering glycomaterials to combat various pathogens including Influenza A viruses, SARS-CoV-2, Herpes Simplex virus, E. coli, and Pseudomonas aeruginosa. With over 40 research articles and 7 patent applications, she leads an active research program at the intersection of chemistry, biology, physics, and emerging technologies. Her research interests center on developing glyco-based synthetic tools to gain experimental insights into infection-related processes. Dr. Bhatia's expertise spans glycomaterials, antimicrobials, polymer chemistry, drug delivery systems, sustainable chemistry, and biomacromolecules. She actively pursues interdisciplinary collaborations, particularly exploring how AI and machine learning can enhance pathogen inhibition strategies. Her work bridges fundamental chemical principles with practical biomedical applications, focusing on multivalent inhibitor design for pathogen neutralization. Analysis of her recent publications reveals a strong focus on glyco-engineered materials for pathogen inhibition, with particular emphasis on influenza viruses, SARS-CoV-2, and bacterial pathogens. Her research demonstrates sophisticated understanding of multivalent binding principles, nanomaterial design, and structure-activity relationships in pathogen inhibition. The work spans from fundamental studies of binding forces to applied therapeutic development, with increasing integration of nanotechnology approaches. Scientific Awards and Recognition: 2024-2025: Research grant from the Royal Society of Chemistry 2024-2027: Research grant from Novo Nordisk Foundation for pandemic anti-influenza drug development 2022: Research-based teaching award from Berlin University Alliance 2022: Shortlisted for the Reimund Stadler Prize 2021: Selected for ProFiL programme for professionalization of women in research and teaching Dr. Bhatia is actively involved in postgraduate supervision and has secured substantial research funding including grants from the German Science Foundation (2021-2024) and Berlin University Alliance (2020-2021). Her international collaborations span Germany, UK, USA, France, Spain, Mexico, and India, reflecting the global impact of her work. She maintains strong industry connections through her research on practical therapeutic applications of glycomaterials. Her laboratory focuses on developing innovative glyco-based materials for pathogen inhibition, with particular emphasis on multivalent binding principles. The research group employs interdisciplinary approaches combining synthetic chemistry, biophysical characterization, and biological testing to develop next-generation antimicrobial and antiviral materials. Current projects include development of pandemic-ready anti-influenza therapeutics and novel materials for combating antibiotic-resistant bacteria.

• Materials Science
• Battery Technology
• Photoelectrochemistry
• +۴ مورد دیگر

Simone Pokrant serves as a University Professor in the Department of Chemistry and Physics of Materials at Paris Lodron University Salzburg (PLUS), leading cutting-edge research in advanced materials for energy applications. Her work spans battery technology, photoelectrochemistry, and nanoscale characterization, with significant contributions to silicon-based anodes, renewable energy materials, and transmission electron microscopy techniques. Her research focuses on materials science for sustainable energy solutions , particularly in developing next-generation battery systems and photoelectrochemical devices. Key areas include silicon-based lithium-ion battery anodes with nanoporous silica scaffolds, degradation mechanisms in energy conversion devices, and plasmonic nanostructures for advanced imaging. She has pioneered cryo-TEM methodologies for biological and solid-state materials analysis, significantly enhancing nanoscale imaging capabilities through the BioMat-TEM facility. Analysis of her 85 publications reveals strong emphasis on practical energy storage solutions and advanced characterization techniques . Recent work (2023-2025) shows increasing focus on hybrid battery systems, plastic waste electrochemical reforming, and precise morphological control of photocatalytic materials. Her publications predominantly appear in high-impact journals like ACS Omega and ACS Sustainable Chemistry & Engineering, demonstrating consistent contributions to materials chemistry and electrochemical engineering. Professor Pokrant actively engages in science communication through media appearances including ORF's Mittagsjournal and public lectures on Salzburg's energy transition. She participates in Scientists4Future Salzburg initiatives, connecting research with societal impact in environmental and energy policy domains. Her current leadership includes five major research projects: ReBi (additive manufacturing, 2022-2027), Degradation processes in photoelectrochemical devices (2021-2025), BioMat-TEM microscopy facility (2021-2025), and Silano battery research (2020-2024). These projects demonstrate sustained research momentum with €2 million invested in the BioMat-TEM facility and cross-border collaborations with Bavarian institutions. She directs the newly implemented cryo-TEM facility at PLUS, enabling atomic-scale imaging of both biological and solid-state materials. Her TEM Workshop series demonstrates commitment to advancing microscopy capabilities within the university community, while her role in Scientists4Future Salzburg connects fundamental research with societal energy transition challenges.

Gilad Ofekمشاهده پروفایل

دانشیار

• Virology
• Structural Biology
• Immunology
• +۴ مورد دیگر

Gilad Ofek is an Associate Professor at the University of Maryland, affiliated with the Institute for Bioscience and Biotechnology Research (IBBR). His research focuses on understanding viral structural organization and immune recognition, particularly for Ebola and HIV-1 viruses. The Ofek lab employs structural biology techniques to study antibody responses and vaccine development. Education: Ph.D., Columbia University, 2001 (Department of Biological Sciences) B.A., University of Chicago, 1993 Postdoctoral Research, National Institutes of Health, 2006 Research Interests: Structural basis of antibody-virus interactions Vaccine design targeting viral glycoproteins Mechanisms of viral immune evasion Development of broadly neutralizing antibodies Publications Trends: Recent work emphasizes HIV and hepatitis C vaccine development, antibody engineering, and structural studies of viral glycoproteins. Key topics include cross-reactive antibodies against Ebola/Marburg viruses and optimization of antibody solubility. Lab & Affiliations: The Ofek Lab is located at IBBR (9600 Gudelsky Dr., Rockville, MD). Their research bridges structural biology and immunology to inform vaccine strategies against emerging viral pathogens.

Jens Voskuhlمشاهده پروفایل

استاد

• Biosupramolecular Chemistry
• Aggregation-Induced Emission (AIE)
• Luminescent Materials
• +۵ مورد دیگر

Prof. Jens Voskuhl is a Professor of Biosupramolecular Chemistry at the University of Duisburg-Essen, leading the Voskuhl Group within the Institut für Organische Chemie (Faculty of Chemistry). His research focuses on luminescent materials, aggregation-induced emission (AIE), and their applications in biomedical imaging, photodynamic therapy, and materials science. He holds a PhD from the University of Münster (2011) and has conducted postdoctoral research at institutions across Germany and the Netherlands. His group develops novel luminophores for imaging, drug delivery, and 3D printing additives, emphasizing interdisciplinary collaborations with physics, biology, and medicine. Education: PhD in Chemistry, University of Münster (2008–2011) MSc and BSc in Chemistry, University of Münster (2002–2008) Research Interests: His work spans biosupramolecular chemistry, AIE phenomena, phosphorescent materials, and nanoparticle design. Key areas include tracking cellular processes, photodynamic therapy using photosensitizers, and stimuli-responsive materials for additive manufacturing. The group’s innovations include luminophores for real-time monitoring of transfection and protein interactions. Publications: Recent work highlights advancements in AIE-based emitters, photoresponsive nanoparticles, and bioimaging agents. Articles focus on material design, emission tuning, and biomedical applications, reflecting trends in interdisciplinary material science and precision medicine. Grants & Labs: Equipped with advanced instrumentation (e.g., emission lifetime spectrometers, fluorescence microscopes), the lab supports PhD/Master’s projects and collaborates with industry. Notable instrumentation includes a new FT300 emission lifetime spectrometer (2025). Labs/Teams: Hosts the Voskuhl Group, collaborating with the Hirschhäuser Group. Current projects include supramolecular ligand design, AIE-driven diagnostics, and functional nanomaterials for biomedical applications.

Olaia Marti Mariمشاهده پروفایل

پژوهشگر

• Medicinal Chemistry
• Organic Chemistry
• Antiviral Drug Discovery
• +۵ مورد دیگر

Olaia Marti Mari is a medicinal chemist specializing in antiviral drug discovery, particularly targeting HIV, Enterovirus A71 (EV-A71), and SARS-CoV-2. She holds a Ph.D. in Organic Chemistry from the Medicinal Chemistry Institute (IQM-CSIC, Spain) and conducted postdoctoral work at Copenhagen University. Her research focuses on synthesizing multivalent compounds, photoswitchable blockers, and PROTACs for viral inhibition. Education: B.S. in Chemistry, University of Valencia M.S. in Organic Chemistry, Universidad Autónoma de Madrid Ph.D. in Organic Chemistry, IQM-CSIC (2017–2022) Research Interests: Olaia's work bridges medicinal chemistry and virology, with emphasis on: Designing multivalent tryptophan derivatives for HIV and EV-A71 inhibition Developing PROTACs for HDAC-targeted therapies Photoswitchable neuromuscular blockers for biomedical applications Small molecules against SARS-CoV-2 using spike protein interaction Structure-activity relationship (SAR) optimization of antiviral agents Nanoparticle-based delivery systems for improved drug bioavailability Scientific Awards: Ramon Madronero Award for Novel Researchers, Spanish Society of Medicinal Chemistry (2021) Esteve Award for Novel Researchers, Spanish Society of Medicinal Chemistry (2019)

• Computational Modeling
• Molecular Simulations
• Polyelectrolytes
• +۷ مورد دیگر

Pablo Miguel Blanco Andres is a Postdoctoral Fellow at the Department of Physics, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU). He is part of the development team for ESPResSo , an open-source molecular dynamics software for coarse-grained systems, and works as a Marie Skłodowska-Curie postdoctoral fellow on the ModEMUS project, modeling nanoparticle transport under ultrasound irradiation through the extracellular matrix. Research Interests: His work focuses on pH-dependent systems, including polyelectrolytes, peptides, and proteins, using computational modeling to study fundamental properties and develop simulation software. Key areas include charge regulation mechanisms, conformational dynamics, and multivalent interactions in biopolymers. Publication Trends: Recent articles highlight advancements in coarse-grained molecular simulations, charge regulation effects in biopolymers, and software development for soft matter systems. Topics span theoretical modeling of polyelectrolyte flexibility, experimental validation of simulation methods, and applications in biomolecular encapsulation. Scientific Awards: Marie Skłodowska-Curie Postdoctoral Fellowship Software Development: Actively contributes to ESPResSo , a versatile tool for simulating soft matter systems, with specific focus on pH-dependent modeling and coarse-grained simulations. Labs & Teams: Collaborates with interdisciplinary teams at NTNU and contributes to international research projects involving computational biophysics and soft matter physics.

• Coronavirus Immunology
• Viral Immunology
• Veterinary Pathology
• +۷ مورد دیگر

Rudra Channappanavar, DVM, PhD is an Associate Professor in Viral Immunology and Veterinary Pathology at the College of Veterinary Medicine, Oklahoma State University. He also serves as faculty for the Oklahoma Center for Respiratory and Infectious Diseases (OCRID). His research focuses on coronavirus-host interactions, mechanisms of protective and pathogenic immunity, and development of antiviral therapeutics. Dr. Channappanavar earned his DVM from Veterinary College, KVAFSU, India, his MVSc in Veterinary Pathology from Indian Veterinary Research Institute, and his PhD in Biology with a focus on Immunology and Infectious Diseases from Oakland University. He completed postdoctoral training at the University of Iowa in Coronavirus Immunobiology and Virology. His research program has three primary focuses: (1) Understanding coronavirus-host interactions and mechanisms of protective and pathogenic immunity, using in vitro and in vivo approaches including knockout and transgenic mouse models; (2) Improving immune responses to human coronavirus infections and vaccinations in the elderly, investigating the role of interferons and monocytes-macrophages in age-related susceptibility; and (3) Identifying and evaluating antiviral and anti-inflammatory agents to reduce coronavirus disease severity, with work on compounds like Camostat Mesylate and amniotic fluid-derived extracellular vesicles. Analysis of his recent publications (2021-2025) reveals a strong focus on SARS-CoV-2 pathogenesis, particularly investigating TLR-mediated immune responses, macrodomain functions in viral replication, and therapeutic approaches including nanoliposome drug delivery systems. His work spans basic molecular virology to translational therapeutic development, with a consistent emphasis on understanding dysregulated immunity in severe coronavirus disease. Dr. Channappanavar has secured significant funding for his research, including multiple NIH grants such as 'Role of ERK1/2 signaling in SARS-CoV-2-induced dysregulated immunity and lung pathology' (2024-2029) and 'Myeloid cell TRAF6 signaling in SARS-CoV-2-induced dysregulated lung immunity' (2024-2026). He also contributes to the Oklahoma Center for Respiratory and Infectious Diseases (OCRID), a NIH-funded Center of Biomedical Research Excellence (CoBRE). As an educator, he teaches PhD Research and Dissertation courses and Undergraduate Research Problems, mentoring the next generation of veterinary and biomedical researchers. His laboratory serves as an important training ground for students interested in viral immunology and respiratory infectious diseases.

• Nanomedicine
• Drug Delivery
• Nanoparticles
• +۳ مورد دیگر

Silvia Pujals Riatós is a Researcher at the Core Facilities Unit of the Institute for Bioengineering of Catalonia (IBEC) in Barcelona, Spain, where she leverages advanced microscopy and nanomaterial characterization expertise to drive innovation in nanomedicine. Her dual role combines facility management with active research in developing next-generation nanocarriers for biomedical applications, particularly in drug delivery and cellular imaging. Her research spans nanomedicine, supramolecular chemistry, and super-resolution microscopy, with emphasis on designing light-activated drug delivery systems, quantifying nanoparticle behavior in biological environments, and engineering tumor-targeted nanotherapeutics. Key focus areas include supramolecular polymers, protein corona analysis, and real-time monitoring of nanocarrier dynamics in complex microenvironments like tumor-on-a-chip models. Her work bridges synthetic chemistry, materials science, and translational medicine to address challenges in cancer therapy and neurodegenerative diseases. Analysis of her 15 most recent publications (2021-2025) reveals three dominant trends: (1) Quantitative characterization of nanomaterial-biological interactions using cutting-edge microscopy techniques like DNA-PAINT and Glyco-PAINT, (2) Development of stimuli-responsive supramolecular systems with optimized stability-release profiles, and (3) Application of engineered nanocarriers in tumor models and cellular activation systems. Collaborations with the Albertazzi group and international teams demonstrate her integrative approach to solving biomedical challenges. As a core facility leader, Dr. Pujals provides critical infrastructure support for IBEC's research ecosystem, enabling high-impact studies through advanced nanomaterial analysis and super-resolution imaging services. Her facility work underpins projects ranging from fundamental protein interaction studies to preclinical cancer models, fostering interdisciplinary innovation across the institute.

• Materials Science
• Biomedical Engineering
• Polymer Chemistry
• +۳ مورد دیگر

Prof. Dr. Kai Licha is a Guest Professor at the Free University of Berlin, affiliated with the Chemistry and Biochemistry Department within the College of Biology, Chemistry, and Pharmacy. His research focuses on biomedical materials, dynamic hydrogels, and polymeric nanosystems for regenerative medicine. Current Research Topics: Dynamic Hydrogels, Functional Biointerfaces, Polymeric Nanosystems Technologies: Antifouling Coatings, Tumor-Targeting Micelles, Thermoresponsive Hydrogels Email: kai.licha@fu-berlin.de | Room E001, Arnimallee 22, Berlin

Cyrus R. Safinyaمشاهده پروفایل

استاد

• Biophysics
• Materials Science
• Structural Biology
• +۷ مورد دیگر

Cyrus R. Safinya is a Distinguished Professor in the Materials Research Lab at the University of California, Santa Barbara , with affiliated appointments in Physics. His research focuses on Macromolecular and Biomolecular Materials , particularly on understanding the fundamental interactions governing supramolecular assemblies of biological significance. His research spans several key areas: Elucidation of interactions between proteins derived from neurons Development of synthetic carriers for nucleic acids (DNA, RNA) for gene delivery and silencing Creation of lipid-based hydrophobic drug carriers for cancer therapeutics Investigation of cytoskeletal protein assemblies in biological systems Development of model systems to understand supramolecular structures in neuronal processes Exploration of principles underlying non-viral gene delivery Study of self-assembly phenomena in soft matter systems Publications from the Safinya Group demonstrate expertise across multiple disciplines: Biophysics of cytoskeletal protein assemblies Materials science of lipid-DNA complexes Neurodegenerative disease modeling Gene delivery and silencing mechanisms Self-assembly and phase behavior of biological macromolecules Advanced imaging techniques for nanoscale structures Scientific honors include: Fellow of the American Association for the Advancement of Science Fellow of the American Physical Society World Class University Visiting Professor at KAIST Henri De Rothschild Foundation Fellowship His group employs synchrotron x-ray diffraction , electron microscopy , and optical imaging techniques to study structural organization of cytoskeletal proteins. They investigate actin , microtubules , and neurofilaments under various conditions to understand how these proteins assemble into functional architectures. Education: PhD in Physics from Massachusetts Institute of Technology BS in Physics and Mathematics from Bates College

• Theoretical Physics
• Density Functional Theory
• Soft Matter Physics
• +۳ مورد دیگر

Roland Roth is a Professor at the Institute for Theoretical Physics within the Department of Physics at the University of Tübingen . His research focuses on theoretical physics, particularly in Density Functional Theory (DFT) , Soft Matter Physics , and Colloid Science . He has contributed extensively to understanding interfacial phenomena, phase transitions, and solvation thermodynamics in complex systems. Research Interests: Roth's work bridges statistical mechanics and computational biophysics , with applications to ion channels , protein solutions , and confined fluids . His studies explore critical Casimir forces , patchy particle models , and geometric effects on fluid behavior . Publications: Recent articles highlight his expertise in DFT methodology , interfacial thermodynamics , and competing interactions in colloidal systems. Topics span from liquid-vapor interfaces to protein phase separation , with methodological advancements in morphometric approaches and solvent-mediated forces . Contact: Email: roland.roth@uni-tuebingen.de

• Polymer Chemistry
• Nanomaterials
• Biointerfaces
• +۳ مورد دیگر

Prof. Dr. Michael Schirner serves as a Guest Professor in the Department of Chemistry at the Free University of Berlin, working within the Haag Research Group led by Prof. Rainer Haag. His role focuses on advancing research in polymer-based nanomaterials and biointerfaces. His research interests encompass Polymer Chemistry, Nanomaterials, Biointerfaces, Antiviral Materials, Biomedical Engineering, and Drug Delivery Systems. He investigates dynamic hydrogels, polymeric nanosystems, and functional biointerfaces for applications including viral inhibition, bacterial capture, and tissue regeneration. Recent publications highlight his contributions to antiviral materials, particularly nanoparticle inhibitors for influenza and SARS-CoV-2, and graphene-based systems for bacterial capture. His work demonstrates a strong trend in leveraging multivalency and electrostatic interactions to develop biomedical solutions.

Mwangiمشاهده پروفایل

استاد

• Veterinary Immunology
• Vaccine Development
• African Swine Fever Virus
• +۴ مورد دیگر

Professor Mwangi is a distinguished faculty member in the Department of Diagnostic Medicine/Pathobiology at Kansas State University's College of Veterinary Medicine. His academic career is centered on developing novel strategies for safely inducing immune protection against microbial pathogens in livestock species. With expertise spanning veterinary immunology and vaccine development, he contributes significantly to the college's mission of advancing animal and public health through research and education. Dr. Mwangi's research interests focus on veterinary immunology with particular emphasis on vaccine development for economically significant livestock pathogens. His work targets African Swine Fever Virus (ASFV) and Bovine Viral Diarrhea Virus (BVDV), developing subunit vaccines, adjuvants, and diagnostic tools. His research program has expanded to include innovative approaches to broadly neutralizing antibodies, HIV envelope trimers in bovine systems, and SARS-CoV-2 research, demonstrating interdisciplinary applications of veterinary immunology principles. Analysis of his recent publications reveals a strong trend toward innovative vaccine platforms including adenovirus-vectored antigens, nanoparticle delivery systems, and mosaic chimeric viral particles. His work spans fundamental immunological mechanisms and practical vaccine applications, with increasing focus on cross-species applications of veterinary immunology principles to human health challenges. Dr. Mwangi teaches DMP 705 Principles of Veterinary Immunology, providing foundational knowledge to veterinary students. His laboratory research supports graduate students and postdoctoral associates working on various aspects of vaccine development and immune response characterization.

Thomas Fuerstمشاهده پروفایل

استاد

• Vaccine Development
• Protein Engineering
• Virology
• +۴ مورد دیگر

Thomas Fuerst is a Professor at the University of Maryland’s Institute for Bioscience and Biotechnology Research (IBBR). His research focuses on developing next-generation vaccines and protein-based therapeutics for infectious diseases like hepatitis C and cancer targets. He holds a Ph.D. in Molecular Genetics (Cornell University, 1984), an MBA in Science Technology and Innovation (George Washington University, 1992), and a B.A. in Biochemistry (UC Berkeley, 1980). His interdisciplinary work integrates virology, immunology, structural biology, and computational biology. Key programs include structure-based vaccine design for enveloped viruses, scaffold-based protein therapeutics for cancer, and polyphosphazene-based delivery systems. Recent advancements include cryo-EM studies of HCV glycoproteins, glycoengineered vaccines, and polyphosphazene nanocomplexes for TLR agonist delivery. Publications (2021–2025) highlight breakthroughs in hepatitis C vaccine candidates, Ebola microneedle patches, and engineered proteases targeting cancer-linked RAS proteins. His lab’s polyphosphazene platforms are central to immunoadjuvant and drug delivery innovations.